Dandu et al., VAM. 2022.
Acute lower extremity ischemia (ALEI) is a vascular emergency with a mortality rate of 15-20%2. Treatment is multifaceted and is typically aimed at restoring blood flow and can be performed surgically, endovascularly, or through a hybrid method.3
Single-center retrospective review of 27 ALEI patients treated with the JETi™ System. 89% of patients met criteria for Rutherford IIa or IIb classification. Patients were treated endovascularly or through a hybrid surgical approach. Adjunctive treatment included angioplasty, stenting and open thrombectomy.
Removal of over 50% of clot burden from target artery, restoration of inline flow. Indications, limb salvage, and major adverse events were reviewed.
Despite a challenging patient population, target thrombus was successfully removed in 85% of JETi™ cases with zero patient deaths at 30 days
|Target Thrombus Successfully Removed||JETi™|
|JETi™ + Adjunctive Procedures*||59%|
|Overall (Includes JETi™ Alone and JETi™ + Adjunctive Procedures)||85%|
*Angioplasty, stenting, open thrombectomy.
JETi™, alone or with adjunctive procedures, was successful in removing target thrombus in 85% of cases.
Zero deaths and only four major limb amputations were reported at 30-days in this challenging population.
JETi™ is a safe and efficacious tool for the treatment of acute lower extremity ischemia (ALEI).